Cipla · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Tender business declined and will continue impacting reported revenues for remaining three quarters of FY27. Private market growing 6.5% but not fully compensating for tender shortfall. Currency volatility (~23% headwind) also affecting reported numbers.
USFDA issued one Form 483 observation during routine inspection at Invand, New York facility. Management committed to addressing within stability timeline. Smaller products affected; not part of major pipeline launches.
Current 16.7% EBITDA margin significantly below steady state due to pre-launch investments (staffed facilities, R&D at 6.8%), inventory write-offs, and geopolitical cost absorption of 1-2% of revenue. Improvement contingent on timely approvals and product ramp-up.
Management clarified that AdAir ($100M+ expectation assumption) now has 3-4 competitors, reducing addressable opportunity. Combined contribution from Ventolin, three respiratory, and peptide assets needed to reach $1B target.
